دورية أكاديمية

Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.

التفاصيل البيبلوغرافية
العنوان: Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
المؤلفون: Weber, Jeffrey S.1 (AUTHOR) jeffrey.weber@nyulangone.org, Poretta, Tayla2 (AUTHOR), Stwalley, Brian D.2 (AUTHOR), Sakkal, Leon A.2 (AUTHOR), Du, Ella X.3 (AUTHOR), Wang, Travis3 (AUTHOR), Chen, Yan3 (AUTHOR), Wang, Yan3 (AUTHOR), Betts, Keith A.3 (AUTHOR), Shoushtari, Alexander N.4,5 (AUTHOR)
المصدر: Cancer Immunology, Immunotherapy. Apr2023, Vol. 72 Issue 4, p955-955. 1p.
مصطلحات موضوعية: *OVERALL survival, *NIVOLUMAB, *MELANOMA, *PLACEBOS
قاعدة البيانات: Academic Search Index
الوصف
تدمد:03407004
DOI:10.1007/s00262-022-03351-w